Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has updated the commercialization of its pioneering CancerQuest 2020 initiative (http://nnw.fm/y6fnc). Based on the updated announcement, the company plans on having its first predictive model of ovarian cancer ready for initial commercialization in revenue-generating projects with Pharma in Q1 2020.
POAI’s CancerQuest 2020 initiative has been driven Helomics, a Predictive Oncology subsidiary which has worked closely with collaborators at the University of Pittsburgh Medical Center (UPMC)-Magee Women’s Hospital to optimize and scale the genomic and transcriptomic data that has been gathered. The first batch of the 400 ovarian cancer subjects has been sequenced, and Helomics is confident that the remaining subjects will move forward on schedule.
The sequencing marks the completion of one of five milestones outlined by POAI in its groundbreaking initiative designed to look at both tumor mutations (genome) as well as tumor gene expression (transcriptome) to build a comprehensive multi-omic picture of ovarian tumor (http://nnw.fm/0EkaB).
“We are also using deep learning on histopathology images of the tumor tissue (tissue-omics) to add an additional dimension to this multi-omic profile,” explained Helomics CTO Dr. Mark Collins. “We believe the combination of the rich multi-omic profile of the tumor and clinical outcome data will allow us to build an AI-driven model of ovarian cancer capable of predicting the tumor drug response and patient outcome (prognosis).”
POAI anticipates receiving the outcome data on the 400 subjects in this retrospective trial from its collaborators at Magee Women’s Hospital shortly. Helomics intends to use the multi-omic data along with existing drug-response profiles and the outcome data to build its first AI-driven predictive model of ovarian cancer; the company expects the model to be commercialized in Q1 2020.
“We believe that this effort will enhance our understanding of the molecular profiles of women with ovarian cancer by using the power of artificial intelligence to create predictive models of therapeutic success,” said Dr. Robert Edwards, professor and chair of the Department of Obstetrics, Gynecology and Reproductive Sciences in the University of Pittsburgh School of Medicine (http://nnw.fm/l8suJ). “We are excited about the potential for AI-powered, evidence-based decision making to increase our ability to bring about successful outcomes.”
In addition, Helomics intends to sequence 50% of its 38,000-plus ovarian tumors in the upcoming year, creating what may be the world’s first comprehensive, actionable multi-omic data set for ovarian cancer. And Helomics doesn’t plan on stopping there. The company is already evaluating ways to sequence other cancers types in its database to build additional AI-driven predictive models, strengthening the company’s presence in both the clinical and research markets.
Predictive Oncology, which began as a joint venture between Skyline Medical and Helomics, is ideally positioned to harness the power of artificial intelligence and work with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for cancer patients.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. The movement toward…
Earlier this month, “Men’s Fitness,” reviewed the unbuzzd clinical trial and described the early study findings as…
Immunotherapy is a relatively new approach in the treatment of cancer and it has had…
PLA gives overlooked biological evidence its own analysis before combining the findings. Published HCC research…
Abdul El-Sayed, a Democrat vying to win a U.S. Senate seat in Michigan, has become…
Many people have been taken by surprise as the flu season gets underway a lot…